Future oncology最新文献_第8页

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression. 欧洲卵巢癌回顾性研究（O'CaRE）：按进展风险因素数量分列的一线治疗结果。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-24 DOI: 10.1080/14796694.2024.2402217

Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker

{"title":"Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.","authors":"Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker","doi":"10.1080/14796694.2024.2402217","DOIUrl":"10.1080/14796694.2024.2402217","url":null,"abstract":"Aim: The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.Patients & methods: Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known BRCA mutation, interval debulking surgery or no surgery, or visible residual disease.Results: Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.Conclusion: Risk profiles should be carefully considered when planning clinical care.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3409-3419"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial. 腱鞘巨细胞瘤患者服用 Vimseltinib 与安慰剂的比较：MOTION 3 期试验简明摘要。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI: 10.1080/14796694.2024.2398893

Nicholas M Bernthal, Sydney Stern, Jean-Yves Blay

{"title":"Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial.","authors":"Nicholas M Bernthal, Sydney Stern, Jean-Yves Blay","doi":"10.1080/14796694.2024.2398893","DOIUrl":"10.1080/14796694.2024.2398893","url":null,"abstract":"What is this summary about?: This article presents a patient-friendly summary of the MOTION phase 3 clinical trial results, which were published in The Lancet in June 2024.The primary goal of the MOTION trial was to understand if treatment with a drug called vimseltinib shrank tumors more than a placebo in participants with symptomatic tenosynovial giant cell tumor, also known as TGCT, for which surgery was unlikely to provide benefit. A placebo is something that looks like the treatment being studied but does not contain any medicine.The MOTION trial compared the effects of vimseltinib versus a placebo using several different outcomes associated with TGCT. These outcomes included tumor size, active range of motion of the affected joint, and several patient-reported quality-of-life measures including physical function, stiffness, overall health, and pain.What were the main conclusions reported by the researchers?: The trial showed that more participants treated with vimseltinib experienced significant tumor shrinkage, as defined by a 30% or greater reduction in tumor size, compared with those receiving a placebo. Participants receiving vimseltinib had improved active range of motion, and they reported improved physical function, stiffness, overall health, and pain, regardless of the amount of tumor shrinkage, compared with participants receiving a placebo. Most side effects in participants treated with vimseltinib were not severe and were manageable.What are the key takeaways?: Vimseltinib was better at shrinking tumors and improving active range of motion, stiffness, pain, and other health measures than the placebo for participants with TGCT. Vimseltinib has the potential to become a new treatment option for patients with TGCT for whom surgery may not provide benefit.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3183-3192"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer. 韩国肺癌患者使用免疫检查点抑制剂的决定因素以及与神经系统不良事件相关的因素。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-25 DOI: 10.1080/14796694.2024.2416378

Sang Hee Kim, Seung Hyeun Lee, Hankil Lee

{"title":"Determinants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer.","authors":"Sang Hee Kim, Seung Hyeun Lee, Hankil Lee","doi":"10.1080/14796694.2024.2416378","DOIUrl":"10.1080/14796694.2024.2416378","url":null,"abstract":"Aim: Studies on immune checkpoint inhibitor (ICI)-related potential neurological adverse events (pNAEs) in Korean lung cancer (LC) patients are scarce. We aimed to examine ICI prescription trends from 2018 to 2022, patient characteristics and factors associated with ICI prescription or concurrent pNAEs in LC.Research design & methods: This observational, cross-sectional study of Korean LC patients investigated four ICIs (pembrolizumab, nivolumab, atezolizumab and durvalumab). The annual ICI prescription rate was calculated by dividing the number of LC patients prescribed ICIs with the total annual number of LC patients. Factors associated with ICI prescriptions or concurrent pNAEs were assessed.Results: The annual ICI prescription rate increased from 3.29% to 9.74% (average: 6.20%). Higher Charlson Comorbidity Index (CCI) scores were associated with more ICI prescriptions (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.07-1.08). Targeted therapy was associated with fewer prescriptions (OR: 0.45; 95% CI: 0.41-0.49). The anti-programmed cell death protein 1 (anti-PD-1) prescription rate was higher in patients with concurrent pNAEs than those without pNAEs (53.09% vs. 50.84%), and this was associated with higher pNAEs prevalence (OR: 1.10; 95% CI: 1.03-1.18).Conclusion: ICI prescription for LC has increased in Korea, CCI and anti-PD-1 increased pNAEs prevalence.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3245-3256"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients. 医生对新诊断的 IV 期非小细胞肺癌患者生物标记物检测策略的偏好。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-18 DOI: 10.1080/14796694.2024.2419351

Anne Shah, Jon Apple, Gabriela Burgos, Josh Lankin, Jesse Cohn, Emily Mulvihill, M Janelle Cambron-Mellott

引用次数: 0

Targeting CDK2 to combat drug resistance in cancer therapy. 靶向 CDK2 对抗癌症治疗中的抗药性。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-29 DOI: 10.1080/14796694.2024.2416382

Sara Kasirzadeh, Jimma Likisa Lenjisa, Shudong Wang

引用次数: 0

Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer. 消融前促甲状腺球蛋白对儿童和青少年分化型甲状腺癌的预后价值。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI: 10.1080/14796694.2024.2433407

Congcong Wang, Yutian Li, Yu Zhang, Guoqiang Wang, Xinfeng Liu, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Gaixia Lu, Renfei Wang, Xufu Wang

{"title":"Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer.","authors":"Congcong Wang, Yutian Li, Yu Zhang, Guoqiang Wang, Xinfeng Liu, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Gaixia Lu, Renfei Wang, Xufu Wang","doi":"10.1080/14796694.2024.2433407","DOIUrl":"10.1080/14796694.2024.2433407","url":null,"abstract":"Aim: To investigate the prognostic value of pre-ablation stimulated thyroglobulin (ps-Tg) in children and adolescents with persistent differentiated thyroid cancer (DTC) following initial radioiodine therapy (RAI).Materials & methods: Patients were classified into \"no clinical evidence of disease\" (NED), \"biochemical persistent disease\" (BPD), and \"structural/functional persistent disease\" (S/FPD) groups, based on their therapeutic response to initial RAI. BPD patients were further categorized as incomplete response (IR) or Non-IR; S/FPD patients were categorized as remission or Non-remission. Receiver operating characteristic (ROC) curves were used to assess the predictive value of ps-Tg for long-term prognosis. Univariate and multivariate regression analyses were performed to identify risk factors for IR in BPD group and Non-remission in S/FPD group.Results: In total, 130 patients were included, with NED (32), BPD (61), and S/FPD (37) patients. Multivariate analysis identified therapeutic response to initial RAI as the only independent predictor of IR in the BPD group. ROC analysis determined an optimal ps-Tg threshold of 112.40 ng/mL for predicting Non-remission in S/FPD patients. Multivariate analysis further confirmed that ps-Tg > 112.4 ng/mL was significantly associated with Non-remission.Conclusions: Findings indicate ps-Tg as a valuable predictor of long-term prognosis in children and adolescents with persistent DTC post initial RAI.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3463-3470"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case-control study. 与脑肿瘤风险相关的线粒体 sirtuins 基因变异：一项病例对照研究。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/14796694.2024.2429948

Maria Fazal Ul Haq, Muhammad Zahid Hussain, Muhammad Shahbaz Haris, Mahmood Akhtar Kayani, Ishrat Mahjabeen

{"title":"Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case-control study.","authors":"Maria Fazal Ul Haq, Muhammad Zahid Hussain, Muhammad Shahbaz Haris, Mahmood Akhtar Kayani, Ishrat Mahjabeen","doi":"10.1080/14796694.2024.2429948","DOIUrl":"10.1080/14796694.2024.2429948","url":null,"abstract":"Background: Previous studies on brain tumors have been performed on the nuclear genome, but limited studies have been reported on the mitochondrial genome. The mitochondrial sirtuin (SIRT3/SIRT4/SIRT5) has been mutated in different cancers. Limited studies have been performed on brain tumors. Isocitrate dehydrogenase (IDH) is an important marker, and polymorphism in the IDH gene has been reported to differentiate the brain tumor subtypes.Aim: The present study was designed to screen mitochondrial sirtuins and IDH polymorphisms in brain tumor patients.Methodology: One thousand blood samples were collected (500 brain tumor patients and 500 controls). Two SNPs for each gene SIRT3 (rs12226697, rs570591), SIRT4 (rs184496260, 1925909), SIRT5 (rs2841522, rs2841523), and one SNP for IDH (rs11554137) was screened using Tetra-ARMS PCR.Results: Logistic regression showed that the mutant genotype of selected SNPs was associated with increased disease incidence compared to wild type. Haplotype analysis and linkage disequilibrium (LD) showed a strong LD in brain tumor patients. Kaplan-Meier analysis showed that mutant allele frequency was found to be associated with a significant decrease in the survival of brain tumor patients.Conclusion: The present study showed that the mutant allele of selected mitochondrial sirtuins' SNP was associated with increased brain tumor risk.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3421-3432"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of the CALM intervention on cancer-related fatigue and heart rate variability in NSCLC: a randomized trial. CALM干预对NSCLC癌症相关疲劳和心率变异性的影响：随机试验。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1080/14796694.2024.2428586

Jiaying Chai, Chen Gan, Yingxue Jia, Runze Huang, Anlong Li, Han Ge, Xinyi Zheng, Lijun Liu, Jian Xu, Ling Cheng, Huaidong Cheng

{"title":"Effects of the CALM intervention on cancer-related fatigue and heart rate variability in NSCLC: a randomized trial.","authors":"Jiaying Chai, Chen Gan, Yingxue Jia, Runze Huang, Anlong Li, Han Ge, Xinyi Zheng, Lijun Liu, Jian Xu, Ling Cheng, Huaidong Cheng","doi":"10.1080/14796694.2024.2428586","DOIUrl":"10.1080/14796694.2024.2428586","url":null,"abstract":"Objectives: To evaluate the effects of CALM intervention on cancer-related fatigue (CRF), quality of life (QOL), and heart rate variability (HRV) in non-small cell lung cancer (NSCLC) patients.Methods: A total of 153 NSCLC patients were enrolled in the study. Participants were randomly assigned to the CALM group and usual care (UC) group. Patients in the CALM group were received 6 CALM intervention sessions over a 12-week period and evaluated using CRF, QOL and HRV at baseline (T0) and after 2, 4, and 6 intervention sessions.Results: The CALM group showed significant differences in total CRF, behavioral/daily life CRF, emotional/affective CRF, sensory/physical CRF, cognitive CRF and QOL before and after CALM intervention sessions (F = 643.47, F = 208.34, F = 354.52, F = 285.69, F = 334.29, F = 245.77, p < 0.001). The CALM group showed significant increases in standard deviation of normal R-R interval (SDNN) and high-frequency power (HF) (z = -4.94, p < 0.001,z = -4.30, p < 0.001). Significant negative correlations were observed between CRF and SDNN, HF and QOL across all participants.Conclusions: The CALM intervention had a positive impact on overall physical and mental health, fatigue reduction, quality of life and autonomic dysfunction in NSCLC patients. Heart rate variability may serve as an observational indicator of physical and mental health.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3289-3300"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis. 艾瑞布林与紫杉醇在乳腺癌中的疗效和安全性比较：系统综述和荟萃分析。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-20 DOI: 10.1080/14796694.2024.2431479

Jialin Zhang, Jingyang Su, Cui Ni, Jinhua Lu

{"title":"Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.","authors":"Jialin Zhang, Jingyang Su, Cui Ni, Jinhua Lu","doi":"10.1080/14796694.2024.2431479","DOIUrl":"10.1080/14796694.2024.2431479","url":null,"abstract":"Aim: We conducted a meta-analysis of published randomized controlled trials to compare the effectiveness and safety of eribulin versus paclitaxel for patients with breast cancer.Methods: We systematically searched multiple databases including Cochrane, PubMed, Medline, and Embase. The primary outcomes analyzed were overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), and adverse events (AEs). These outcomes were evaluated using RevMan5.3 software.Results: A total of 5 studies were included in the analysis. Compared to paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs not only extended the overall survival of patients but also improved the disease control rate (DCR) [risk ratio (RR) 0.98, (95% confidence intervals (CI): 0.70, 1.38), p = 0.92]. Hematological system diseases [RR 1.18 (95% CI: 1.07, 1.31), p = 0.002] were the most frequently observed adverse event with eribulin, while paclitaxel was more likely to cause nervous system lesion [RR 0.66 (95% CI: 0.54, 0.80), p < 0.0001].Conclusion: Compared with paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs can also prolong the PFS and OS of BC patients. Our recommendation is to use eribulin plus other chemotherapy drugs to treat advanced BC and to continuously monitor and manage the drug-related adverse events.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3507-3517"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study. 芬兰转移性黑色素瘤一线免疫疗法或靶向疗法的实际效果：一项队列研究。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-09-30 DOI: 10.1080/14796694.2024.2403329

Kalle E Mattila, Leena Tiainen, Johanna Vikkula, Anna Kreutzman, Mia Engström-Risku, Kai Kysenius, Olivia Hölsä, Sari Hernesniemi, Päivikki Hemmilä, Anssi Pystynen, Siru Mäkelä

引用次数: 0